Nathan O. Fuller
AstraZeneca (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Asymmetric Synthesis and Catalysis, Cholinesterase and Neurodegenerative Diseases, Advanced Synthetic Organic Chemistry, Asymmetric Hydrogenation and Catalysis
Most-Cited Works
- → Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6(2018)136 cited
- → Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors(2017)78 cited
- → An improved model for fragment-based lead generation at AstraZeneca(2016)77 cited
- → Investigation of the Rh-Catalyzed Asymmetric Reductive Aldol Reaction. Expanded Scope Based on Reaction Analysis(2004)62 cited
- → Fragment-based Differential Targeting of PPI Stabilizer Interfaces(2020)50 cited
- → CoREST Complex-Selective Histone Deacetylase Inhibitors Show Prosynaptic Effects and an Improved Safety Profile To Enable Treatment of Synaptopathies(2018)49 cited
- → Optimization of a Natural Product-Based Class of γ-Secretase Modulators(2012)46 cited
- → Identification of an Orally Efficacious Matrix Metalloprotease 12 Inhibitor for Potential Treatment of Asthma(2009)39 cited
- → Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD)(2011)34 cited
- → Modulation of Gamma-Secretase for the Treatment of Alzheimer's Disease(2012)27 cited